Pharmacist Medication Insights: Galcanezumab (Emgality) for Migraine

Video

Galcanezumab-gnlm (Emgality) is a CGRP antagonist indicated in adults for the preventive treatment of migraine and treatment of episodic cluster headache.

Galcanezumab-gnlm (Emgality) is a calcitonin-gene related peptide (CGRP) antagonist indicated in adults for the preventive treatment of migraine and treatment of episodic cluster headache.

Galcanezumab-gnlm was approved by the FDA in September 2018 for the preventive treatment of migraine in adults. The drug selectively binds to the CGRP and is the only CGRP monoclonal antibody with response rates in the episodic migraine headache population of ≥50%, ≥75%, and 100% reduction from baseline in monthly migraine headache days over months 1 to 6.

Galcanezumab-gnlm was approved by the FDA in June 2019 for the treatment of episodic cluster headache in adults.

Related Videos
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Image credit: motortion | stock.adobe.com - Young depressed woman talking to lady psychologist during session, mental health
Image credit:  JPC-PROD | stock.adobe.com - Choosing method of contraception : Birth control pills, an injection syringe, condom, IUD-method, on grey
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Health care provider examining MRI images of patient with multiple sclerosis -- Image credit: New Africa | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.